SEC Comment Letter for Oruka Therapeutics, Inc. (ORKA) (CIK 0000907654) (ORKA) — May 5, 2017
Oruka Therapeutics, Inc. (ORKA) (CIK 0000907654)
Date: May 5, 2017 · CIK: 0000907654 · Accession: 0000000000-17-015946
AI Filing Summary & Sentiment
Reasoning
Letter
May 5, 2017 Michael Bristow President and Chief Executive Officer ARCA biopharma, Inc. 11080 CirclePoint Road, Suite 140 Westminster, CO 80020 ARCA biopharma, Inc. Registration Statement on Form S-3 Filed April 25, 2017 File No. 333-217459Re: Dear Dr. Bristow : This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Brent D. Fassett
Show Raw Text
May 5, 2017
Michael Bristow
President and Chief Executive Officer
ARCA biopharma, Inc.
11080 CirclePoint Road, Suite 140
Westminster, CO 80020
ARCA biopharma, Inc.
Registration Statement on Form S-3
Filed April 25, 2017
File No. 333-217459Re:
Dear Dr. Bristow :
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dorrie Yale at 202-551-8776 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Brent D. Fassett